Aldosterone as a Possible Contributor to Eye Diseases

Endocrinology. 2022 Dec 19;164(2):bqac201. doi: 10.1210/endocr/bqac201.

Abstract

Aldosterone, an effector molecule of the renin-angiotensin-aldosterone system (RAAS), has been receiving more attention in the field of ophthalmology because of its possible role in the pathogenesis of various eye diseases or abnormalities; it may even become a target for their treatment. Primary aldosteronism, a typical model of a systemic aldosterone excess, may cause vision loss due to various ocular diseases, such as retinal vein occlusion, central serous chorioretinopathy, and, possibly glaucoma. RAAS components are present in various parts and types of cells present in the eye. Investigations of the local RAAS in various animal models of diabetic macular edema, retinal vein occlusion, retinopathy of prematurity, central serous chorioretinopathy, and glaucoma have found evidence that aldosterone or mineralocorticoid receptors may exacerbate the pathology of these disorders. Further studies are needed to elucidate whether the modulation of aldosterone or mineralocorticoid receptors is an effective treatment for preventing vision loss in patients with eye diseases.

Keywords: aldosterone; glaucoma; laser speckle flowgraphy; retinal diseases; retinal ganglion cell death; rodent model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone
  • Animals
  • Central Serous Chorioretinopathy* / complications
  • Diabetic Retinopathy* / etiology
  • Glaucoma* / complications
  • Macular Edema* / complications
  • Receptors, Mineralocorticoid
  • Renin-Angiotensin System
  • Retinal Vein Occlusion* / etiology

Substances

  • Aldosterone
  • Receptors, Mineralocorticoid